A Teleheath tDCS Approach to Decrease Cannabis Use

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT05005013
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
21 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Transcranial Direct Current Stimulation (tDCS) — OTHER
    tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
  • Sham - Transcranial Direct Current Stimulation (tDCS) — OTHER
    The tDCS device is programmed to mimic active tDCS.
  • Mindfulness — OTHER
    Participants will follow an audio track for guided mindfulness during the stimulation.

Study Details

The study aims to evaluate the effect of Dorsolateral Prefrontal Cortex (DLPFC) Transcranial Direct Current Stimulation (tDCS) in decreasing distress and cannabis use. 46 participants with Relapse Remitting Multiple Sclerosis (RRMS), Cannabis Use Disorder (CUD) and elevated distress (K10 score of 10-35) will be recruited.

Key Dates

Start date
Sep 13, 2022
Status verified
Jun 2025
Primary completion
Feb 14, 2024
Completion
May 22, 2024

Study Design

Enrollment
52 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Active tDCS + Mindfulness
  • Sham Comparator: Sham tDCS + Mindfulness

Primary Outcome Measure

Change in Kessler Psychological Distress Scale (K10) Score [ Time Frame: Baseline, End of Intervention (Week 4) ]

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone HealthNew YorkNew York10017-

Find similar trials in New York, NY

By condition
Multiple sclerosis
By specialty
NeurologyBrain disordersAutoimmune disease
By research site
NYU Langone Health· New York, NY

Related Studies